SCHEMBL9944110

SCHEMBL9944110

Cc1cc(NC(=O)c2cc(Cl)c(C)c(OC3CCC3)c2)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 7/20 0.47
PDE4B Q07343 7/20 0.47
PDE4C Q08493 7/20 0.47
PDE4D Q08499 7/20 0.47
PDE5A O76074 3/20 0.47
PDE1A P54750 1/20 0.47
PDE1B Q01064 1/20 0.47
PDE1C Q14123 1/20 0.47
RORC P51449 1/20 0.43
NR1H4 Q96RI1 1/20 0.40
CPT2 P23786 1/20 0.40
CPT1A P50416 1/20 0.40
CPT1B Q92523 1/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458110 0.91 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL9944118 0.90 RARA (0.45) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL9944107 0.89 PDE4A (0.54) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL1458497 0.89 PDE4D (0.50) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL1458266 0.89 PDE4D (0.49) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL1458444 0.87 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL1457736 0.87 RAB9A (0.51) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL9944228 0.84 PDE5A (0.47) PDE4APDE4BPDE4CPDE4DPDE5A
SCHEMBL9944111 0.83 NR1H4 (0.47) PDE4APDE4BPDE4CPDE4DNR1H4
SCHEMBL9944102 0.83 NPC1 (0.48) RORCNR1H4NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PDE4A 358/4885PDE4B 512/4885PDE4C 840/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PDE4A 358/4885PDE4B 512/4885PDE4C 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.